NI201900029A - COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING - Google Patents

COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING

Info

Publication number
NI201900029A
NI201900029A NI201900029A NI201900029A NI201900029A NI 201900029 A NI201900029 A NI 201900029A NI 201900029 A NI201900029 A NI 201900029A NI 201900029 A NI201900029 A NI 201900029A NI 201900029 A NI201900029 A NI 201900029A
Authority
NI
Nicaragua
Prior art keywords
compounds
general formula
benzo
thiophene compounds
sting agonists
Prior art date
Application number
NI201900029A
Other languages
English (en)
Inventor
D Altman Michael
D Cash Brandon
Chang Wonsuk
N Cumming Jared
M Haidle Andrew
J Henderson Timothy
P Jewell James
A Larsen Matthew
Liang Rui
Lim Jongwon
Lu Min
D Otte Ryan
Siu Tony
Wesley Trotter Benjamin
Tyagarajan Sriram
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NI201900029A publication Critical patent/NI201900029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan los compuestos de fórmula general (Ia), los compuestos de fórmula general (Ia'), los compuestos de fórmula general (Ib), los compuestos de fórmula general (Ib'), los compuestos de fórmula general (I), los compuestos de fórmula general (I'), y sus sales farmacéuticamente aceptables, en las que R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, y X3 se definen en el presente documento, que pueden ser útiles como inductores de la producción de interferones de tipo I, específicamente como agentes activos de STING. También se proporcionan procedimientos para la síntesis y uso de compuestos de la divulgación.
NI201900029A 2016-10-04 2019-04-03 COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING NI201900029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662404062P 2016-10-04 2016-10-04

Publications (1)

Publication Number Publication Date
NI201900029A true NI201900029A (es) 2019-05-13

Family

ID=60084122

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900029A NI201900029A (es) 2016-10-04 2019-04-03 COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING

Country Status (40)

Country Link
US (3) US10414747B2 (es)
EP (1) EP3523287B1 (es)
JP (1) JP6636673B2 (es)
KR (1) KR102312721B1 (es)
CN (1) CN110036001B (es)
AR (1) AR109788A1 (es)
AU (1) AU2017339418C1 (es)
BR (1) BR112019006816A8 (es)
CA (1) CA3038903C (es)
CL (1) CL2019000902A1 (es)
CO (1) CO2019003349A2 (es)
CR (1) CR20190168A (es)
CY (1) CY1124837T1 (es)
DK (1) DK3523287T3 (es)
DO (1) DOP2019000083A (es)
EA (1) EA037626B1 (es)
EC (1) ECSP19026680A (es)
ES (1) ES2893532T3 (es)
GE (1) GEP20217285B (es)
HR (1) HRP20211617T1 (es)
HU (1) HUE056502T2 (es)
IL (1) IL265678B2 (es)
JO (1) JOP20190070B1 (es)
LT (1) LT3523287T (es)
MA (1) MA46452B1 (es)
MD (1) MD3523287T2 (es)
MX (1) MX2019003829A (es)
MY (1) MY196383A (es)
NI (1) NI201900029A (es)
PE (1) PE20190705A1 (es)
PH (1) PH12019500712A1 (es)
PL (1) PL3523287T3 (es)
PT (1) PT3523287T (es)
RS (1) RS62410B1 (es)
SG (1) SG10202008647TA (es)
SI (1) SI3523287T1 (es)
TN (2) TN2020000159A1 (es)
TW (1) TWI796306B (es)
UA (1) UA125223C2 (es)
WO (1) WO2018067423A1 (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3429596T (pt) 2016-03-18 2022-11-25 Immune Sensor Llc Compostos de dinucleotídeos cíclicos e métodos de utilização
IL264049B2 (en) 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
HUE056502T2 (hu) * 2016-10-04 2022-02-28 Merck Sharp & Dohme Benzo[b]tiofén vegyületek mint STING agonisták
CR20190181A (es) 2016-10-14 2019-08-21 Prec Biosciences Inc Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
CN110650976B (zh) 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
CA3071538A1 (en) * 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment
US11638716B2 (en) 2017-08-31 2023-05-02 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US20200330556A1 (en) * 2017-10-05 2020-10-22 Glaxosmithkline Intellectual Property Development Limited Methods for Administering STING Agonists
BR112020009126A2 (pt) 2017-11-10 2020-10-20 Takeda Pharmaceutical Company Limited compostos do modulador sting e métodos de fabricação e uso
WO2019109001A1 (en) 2017-12-01 2019-06-06 The Texas A&M University System Angelman syndrome antisense treatment
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
EP3774765A4 (en) * 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
JP7326319B2 (ja) 2018-04-03 2023-08-15 メルク・シャープ・アンド・ドーム・エルエルシー Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
GB201807924D0 (en) * 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2019227007A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
EP3826660A1 (en) * 2018-07-26 2021-06-02 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
IL281247B1 (en) 2018-09-06 2024-09-01 Daiichi Sankyo Co Ltd New derivatives of cyclic dinucleotides and their antibody-drug conjugates
SG11202103573YA (en) 2018-10-11 2021-05-28 Ono Pharmaceutical Co STING Agonistic Compound
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3873903B1 (en) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
CN111393404B (zh) * 2019-01-02 2023-02-17 中国科学院上海药物研究所 一类苯并噻吩类化合物及其药物组合物及应用
CN111393405B (zh) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
KR20210137518A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113543851A (zh) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
CN111848573B (zh) * 2019-04-30 2023-04-07 四川科伦博泰生物医药股份有限公司 苯并噻吩酰胺类化合物及其制备方法和用途
CN113518776B (zh) * 2019-04-30 2024-03-26 四川科伦博泰生物医药股份有限公司 苯并噻吩类化合物及其制备方法和用途
CN111848572B (zh) * 2019-04-30 2023-03-31 四川科伦博泰生物医药股份有限公司 酰胺类化合物及其制备方法和用途
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
TW202120500A (zh) 2019-08-02 2021-06-01 美商梅爾莎納醫療公司 干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
JP7485399B2 (ja) * 2019-08-21 2024-05-16 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの単環式アゴニスト
EP4017593A1 (en) * 2019-08-21 2022-06-29 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
KR20220100607A (ko) * 2019-10-28 2022-07-15 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 5원 헤테로사이클릭 옥소카르복실산 화합물 및 이의 의약 용도
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021113679A1 (en) * 2019-12-06 2021-06-10 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
BR112022015283A2 (pt) 2020-03-06 2022-09-20 Daiichi Sankyo Co Ltd Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
WO2021205631A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 Ｓｔｉｎｇ作動化合物
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
MX2022014191A (es) 2020-05-13 2022-12-07 Massachusetts Inst Technology Composiciones de microdispositivos polimericos y su uso en la inmunoterapia de cancer.
CN113861161A (zh) * 2020-06-30 2021-12-31 上海海和药物研究开发股份有限公司 一种芳基并芳杂环衍生物及其制备方法和用途
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
PE20230779A1 (es) 2020-08-07 2023-05-09 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
CA3191395A1 (en) 2020-09-02 2022-03-10 Daiichi Sankyo Company, Limited Novel endo-.beta.-n-acetylglucosaminidase
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
CN113429384B (zh) * 2021-05-12 2022-04-08 中山大学附属第五医院 一类干扰素基因刺激因子靶向的放射性pet显像剂
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
CN117836007A (zh) * 2021-07-13 2024-04-05 南京大学 一种pt偶联物及其用途
CN113429387B (zh) * 2021-07-27 2022-10-28 中国药科大学 一种苯并[b]硒吩类STING调控剂、其制备方法及用途
CN115772154B (zh) * 2021-09-08 2024-04-30 上海交通大学 一类含有氘取代的苯并噻吩类衍生物及其制备与用途
TW202346322A (zh) 2022-03-02 2023-12-01 日商第一三共股份有限公司 含Ｆｃ分子之製造方法
WO2023211940A1 (en) * 2022-04-25 2023-11-02 The Regents Of The University Of Michigan Sting agonists, formulations, and uses thereof
WO2023211930A1 (en) * 2022-04-25 2023-11-02 The Regents Of The University Of Michigan Dual functioning immune modulating compounds, formulations, and uses thereof
WO2024175086A1 (zh) * 2023-02-24 2024-08-29 深圳真实生物医药科技有限公司 芳基三并环类sting激动剂及其用途
CN116354922A (zh) * 2023-03-31 2023-06-30 药康众拓(江苏)医药科技有限公司 氘代苯并噻吩类化合物及其药物组合物和用途
WO2024211577A1 (en) 2023-04-05 2024-10-10 Massachusetts Institute Of Technology Hybrid polymeric systems and methods of use thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB532822A (en) * 1939-08-11 1941-01-31 John David Kendall Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters
GB1383114A (en) * 1972-06-22 1975-02-05 English Electric Valve Co Ltd Magnetrons
US4342691A (en) 1980-04-28 1982-08-03 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
US4342689A (en) 1980-04-28 1982-08-03 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
US4342690A (en) 1980-04-28 1982-08-03 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
US4299769A (en) * 1980-04-28 1981-11-10 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
EP0146243A1 (en) 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
DE68924308T2 (de) * 1988-07-11 1996-04-04 Akzo Nobel Nv Pyridazinon-Derivate.
EP0664792B1 (en) 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
US5569655A (en) 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
JP2002517390A (ja) 1998-06-03 2002-06-18 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
US6262055B1 (en) 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
CA2404002A1 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
CA2437898A1 (en) 2001-02-26 2002-09-06 Pharma Pacific Pty. Ltd Interferon-alpha induced gene
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
JP2007504228A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼組成物
WO2005087238A2 (en) 2004-03-15 2005-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
WO2010047774A2 (en) 2008-10-20 2010-04-29 The Texas A & M University System Inhibitors of mycobacterium tuberculosis malate synthase, methods of marking and uses thereof
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2012068702A1 (zh) * 2010-11-23 2012-05-31 中国医学科学院医药生物技术研究所 苯并五元不饱和杂环类化合物及其制备方法
JP5887947B2 (ja) 2011-03-28 2016-03-16 ソニー株式会社 透明導電膜、ヒータ、タッチパネル、太陽電池、有機ｅｌ装置、液晶装置および電子ペーパ
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
SG11201407875UA (en) 2012-06-08 2014-12-30 Aduro Biotech Compostions and methods for cancer immunotherapy
CN103840995B (zh) 2012-11-26 2017-10-24 华为技术有限公司 Ip报文处理方法、装置及网络系统
WO2014093936A1 (en) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CA2895175C (en) 2012-12-19 2021-06-01 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
JP6400082B2 (ja) 2013-05-18 2018-10-03 アデュロ バイオテック，インコーポレイテッド 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
WO2015077354A1 (en) * 2013-11-19 2015-05-28 The University Of Chicago Use of sting agonist as cancer treatment
EP3071229A4 (en) 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN103908468B (zh) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
MX2016015928A (es) 2014-06-04 2017-03-20 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting.
WO2015189117A1 (de) 2014-06-12 2015-12-17 Bayer Pharma Aktiengesellschaft Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung
PT3233882T (pt) 2014-12-16 2020-01-21 Kayla Therapeutics Dinucleótidos cíclicos fluorados para a indução de citocinas
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
EP3233089A4 (en) 2014-12-17 2018-11-14 Lipogen LLC Method of treating cancer with cgamp or cgasmp
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TN2017000375A1 (en) * 2015-03-10 2019-01-16 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2017011622A1 (en) 2015-07-14 2017-01-19 Spring Bank Pharmaceuticals, Inc. Compounds and compositions that induce rig-i-and other pattern recongnition receptors
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
US10738074B2 (en) 2015-08-13 2020-08-11 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as STING agonists
US9809597B2 (en) 2015-08-20 2017-11-07 The Board Of Trustees Of The Leland Stanford Junior University Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
WO2017075477A1 (en) 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
EP3366691A1 (en) 2015-12-03 2018-08-29 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017100305A2 (en) 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition of antibody construct-agonist conjugates and methods of use thereof
US10604542B2 (en) 2016-01-11 2020-03-31 Innate Tumor Immunity, Inc. Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
PT3429596T (pt) 2016-03-18 2022-11-25 Immune Sensor Llc Compostos de dinucleotídeos cíclicos e métodos de utilização
CA3019628A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
KR102527786B1 (ko) 2016-04-07 2023-04-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조정제로서 유용한 헤테로시클릭 아미드
PE20190971A1 (es) 2016-06-13 2019-07-09 Glaxosmithkline Ip Dev Ltd Compuestos quimicos
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
HUE056502T2 (hu) * 2016-10-04 2022-02-28 Merck Sharp & Dohme Benzo[b]tiofén vegyületek mint STING agonisták
AU2018311965A1 (en) * 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
CA3071538A1 (en) * 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment

Also Published As

Publication number Publication date
JP6636673B2 (ja) 2020-01-29
IL265678A (en) 2019-05-30
US20180093964A1 (en) 2018-04-05
EA037626B1 (ru) 2021-04-22
PT3523287T (pt) 2021-10-06
CY1124837T1 (el) 2022-11-25
US20190337917A1 (en) 2019-11-07
SI3523287T1 (sl) 2021-11-30
KR20190056432A (ko) 2019-05-24
EP3523287B1 (en) 2021-09-01
EA201990846A1 (ru) 2019-08-30
EP3523287A1 (en) 2019-08-14
HUE056502T2 (hu) 2022-02-28
CO2019003349A2 (es) 2019-04-12
US10703738B2 (en) 2020-07-07
JOP20190070A1 (ar) 2019-04-04
US10414747B2 (en) 2019-09-17
BR112019006816A2 (pt) 2019-07-30
MY196383A (en) 2023-03-28
UA125223C2 (uk) 2022-02-02
CA3038903C (en) 2021-07-27
MA46452B1 (fr) 2021-10-29
DK3523287T3 (da) 2021-10-18
HRP20211617T1 (hr) 2022-03-04
BR112019006816A8 (pt) 2023-02-07
AR109788A1 (es) 2019-01-23
GEP20217285B (en) 2021-08-10
LT3523287T (lt) 2021-11-10
IL265678B2 (en) 2023-06-01
JOP20190070B1 (ar) 2023-09-17
KR102312721B1 (ko) 2021-10-13
CN110036001A (zh) 2019-07-19
PE20190705A1 (es) 2019-05-17
TN2020000158A1 (en) 2022-04-04
MA46452A (fr) 2021-04-07
ECSP19026680A (es) 2019-04-30
PL3523287T3 (pl) 2021-12-20
AU2017339418B2 (en) 2020-04-16
TW201817723A (zh) 2018-05-16
ES2893532T3 (es) 2022-02-09
SG10202008647TA (en) 2020-10-29
CL2019000902A1 (es) 2019-06-21
MX2019003829A (es) 2019-07-01
RS62410B1 (sr) 2021-10-29
US10730849B2 (en) 2020-08-04
TN2020000159A1 (en) 2022-04-04
US20190337918A1 (en) 2019-11-07
TWI796306B (zh) 2023-03-21
PH12019500712A1 (en) 2019-12-02
AU2017339418C1 (en) 2020-12-17
CA3038903A1 (en) 2018-04-12
WO2018067423A1 (en) 2018-04-12
MD3523287T2 (ro) 2021-12-31
CN110036001B (zh) 2022-03-22
CR20190168A (es) 2019-05-17
AU2017339418A1 (en) 2019-04-18
JP2019534876A (ja) 2019-12-05
DOP2019000083A (es) 2019-07-15

Similar Documents

Publication Publication Date Title
NI201900029A (es) COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CO7141456A2 (es) Derivados de aril-sultamo como moduladores de rorc
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
ECSP15025947A (es) Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
CO2018003367A2 (es) Benzamidas sustituidas con isoxazolina y análogos como insecticidas
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CO2017009994A2 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
CL2022000145A1 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
UY39694A (es) Novedosos compuestos útiles como agonistas de sting y sus usos
UY39705A (es) Novedosos compuestos útiles como agonistas de sting y sus usos
GT201100039A (es) Agentes antifúngicos
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
ECSP11010817A (es) Agentes antifúngicos